Increased Proteinuria is Associated with Increased Aortic Arch Calcification, Cardio-Thoracic Ratio, Rapid Renal Progression and Increased Overall and Cardiovascular Mortality in Chronic Kidney Disease

Wei-Yu Su1*, Pei-Yu Wu2,3,4*, Jiun-Chi Huang2,3,4, Szu-Chia Chen2,3,4,5, Jer-Ming Chang2,4

1. Department of General Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 2. Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 3. Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 4. Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 5. Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

*Both are equal contributors.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

Background: Patients with chronic kidney disease (CKD) are associated with high prevalence rates of proteinuria, vascular calcification and cardiomegaly. In this study, we investigated relationships among proteinuria, aortic arch calcification (AoAC) and cardio-thoracic ratio (CTR) in patients with CKD stage 3A-5. In addition, we investigated correlations among proteinuria and decline in renal function, overall and cardiovascular (CV) mortality.

Methods: We enrolled 482 pre-dialysis patients with CKD stage 3A-5, and determined AoAC and CTR using chest radiography at enrollment. The patients were stratified into four groups according to quartiles of urine protein-to-creatinine ratio (UPCR).

Results: The patients in quartile 4 had a lower estimated glomerular filtration rate (eGFR) slope, and higher prevalence rates of rapid renal progression, progression to commencement of dialysis, overall and CV mortality. Multivariable analysis showed that a high UPCR was associated with high AoAC (unstandardized coefficient β: 0.315; p = 0.002), high CTR (unstandardized coefficient β: 1.186; p = 0.028) and larger negative eGFR slope (unstandardized coefficient β: -2.398; p < 0.001). With regards to clinical outcomes, a high UPCR was significantly correlated with progression to dialysis (log per 1 mg/g; hazard ratio [HR], 2.538; p = 0.003), increased overall mortality (log per 1 mg/g; HR, 2.292; p = 0.003) and increased CV mortality (log per 1 mg/g; HR, 3.195; p = 0.006).

Conclusions: Assessing proteinuria may allow for the early identification of high-risk patients and initiate interventions to prevent vascular calcification, cardiomegaly, and poor clinical outcomes.

Key words: proteinuria; aortic arch calcification; cardio-thoracic ratio; rapid renal progression; overall mortality; cardiovascular mortality; chronic kidney disease

Introduction

Patients with chronic kidney disease (CKD) are at a high risk of end-stage renal disease (ESRD) and cardiovascular (CV) and all-cause mortality (1). Patients with CKD are associated with many subclinical CV risk factors that may cause rapid renal progression, CV and overall mortality. One of the most important markers for progressive renal function decline, CV and overall mortality in CKD
patients is proteinuria (2). Many studies have reported an association between elevated albuminuria and CV disease, even if albuminuria is at the upper end of the normal range (threshold 30 mg/g) (3). In addition, vascular calcification (VC) in the aorta has been reported to be a risk factor for CV morbidity and mortality in patients on long-term dialysis (1). VC is commonly seen in patients with CKD or ESRD (4).

Chest radiography is a non-invasive, fast and inexpensive tool used to evaluate aortic arch calcification (AoAC) and cardiothoracic ratio (CTR) in daily practice. AoAC identified by chest radiography has been associated with pulse pressure, intima-media thickness of the common carotid artery, CV events, and an increased risk of CV mortality in the general population (5,6). CTR is an easily obtainable parameter which has been associated with left ventricular size, and a high CTR is considered to represent an increased left ventricular mass (LVM), and even left ventricular hypertrophy (7). In patients undergoing maintenance hemodialysis, a high CTR has been independently associated with a high risk of all-cause mortality and CV events (8). In addition, associations among AoAC and CTR and a decline in renal function have been reported in patients with CKD stage 3-5 (9). In our recent study, we also found that increased AoAC and cardiomegaly were associated with a rapid decline in renal function and increased CV mortality in patients with CKD (10).

Nevertheless, associations among the degree of proteinuria and AoAC and CTR in patients with CKD have not been thoroughly investigated. Therefore, the aim of this study was to evaluate relationships among proteinuria and AoAC and CTR in patients with CKD stage 3A-5. In addition, we investigated correlations among proteinuria and a decline in renal function, overall and CV mortality.

**Study Patients and Methods**

**Study Patients and Design**

We consecutively enrolled 638 pre-dialysis patients diagnosed with CKD stage 3A-5 according to the guidelines of the Kidney Disease Improving Global Outcomes 2012 (KDIGO 2012) (11) from the internal medicine outpatient department of a regional hospital in southern Taiwan from March 2007 to January 2016. The patients all had evidence of kidney damage lasting for > 3 months, and they were classified as having CKD stages 3A, 3B, 4 and 5 according to an estimated glomerular filtration rate (eGFR) of 45 to 59 mL/min/1.73 m², 30 to 44 mL/min/1.73 m², 15 to 29 mL/min/1.73 m², and < 15 mL/min/1.73 m², respectively. We excluded 67 patients who had < three recorded measurements of eGFR during the follow-up period. We also excluded 89 patients who were followed up for < 6 months to avoid incomplete observations of changes in renal function. The remaining 482 patients (mean age 65.5 ± 12.2 years, 283 males) were included in this study. The study protocol was approved by the Institutional Review Board of Kaohsiung Medical University Hospital, and all participants provided written informed consent to participate in this study. The methods were carried out in accordance with the approved guidelines.

**Evaluation of AoAC and CTR by Chest X-Ray**

All of the included patients received chest X-rays, which were reviewed by a single experienced radiologist who was blinded to the clinical data of the patients. AoAC was assessed using a scale developed by Ogawa et al. (12) which classifies the aortic arch into 16 sections according to its circumference, and the number of calcified sections was counted and recorded for each patient. CTR was also calculated from the X-rays as the transverse diameter of the cardiac silhouette divided by that of the chest.

**Demographic, Medical and Laboratory Data**

The following baseline demographic, medical and laboratory variables were recorded: age, sex, smoking history (ever vs. never), presence of cerebrovascular disease, coronary artery disease, hypertension, diabetes mellitus, body mass index, systolic blood pressure, diastolic blood pressure, levels of triglycerides, total cholesterol, fasting glucose, hemoglobin, total calcium, phosphorous, calcium-phosphorous product, eGFR, uric acid, parathyroid hormone (PTH) and UPCR. The use of medications including angiotensin II receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEIs) and calcium-based phosphate binders was also recorded. The demographic variables were obtained from baseline records, and the medical data was obtained from a chart review. Fasting blood and urine samples were collected from the patients within 1 month of enrollment, and the laboratory data were obtained (COBAS Integra 400, Roche Diagnostics GmbH, D-68298 Mannheim), and the compensated Jaffé method (kinetic alkaline picrate) was used to calculate levels of serum creatinine (Roche/Integra 400 Analyzer, Roche Diagnostics) as previously described (13). EGFR was calculated using the Modification of Diet in Renal Disease-4 equation (14).

**Assessment of Decline in Renal Function and Definition of Rapid Renal Progression**

The rate of decline in renal function was evaluated using the eGFR slope, which was plotted
using at least three measurements and defined as the regression coefficient between eGFR and time. A decline > 3 ml/min/1.73 m²/year was defined as rapid renal progression (15). Renal function data were censored in the patients who progressed to renal replacement therapy. The other patients were followed until September 2018.

Definition of Renal End Point

The renal endpoint was defined as starting dialysis. Renal function data were censored at the initiation of renal replacement therapy for those who reached the endpoint. The other patients were followed until September 2018. The date of starting dialysis was determined according to the regulations for dialysis therapy of the National Health Insurance program in Taiwan, which are based on uremic symptoms and signs, nutrition status, and laboratory data.

Definition of Overall and CV Mortality

Cases of overall and CV mortality were defined by two cardiologists from medical records. Disagreements were resolved after consultation with a third cardiologist. The patients were followed until death or September 2018, whichever occurred first.

Reproducibility

The reproducibility of AoAC was evaluated by an experienced radiologist and a medical doctor in 30 patients who were selected at random. The mean percent error was calculated as the difference divided by the average of the two observations, and was 12.3 ± 12.3% in this study.

Statistical Analysis

Statistical analysis was performed using SPSS 19.0 for Windows (SPSS Inc. Chicago, USA). Data were expressed as percentage, mean ± standard deviation, or median (25th-75th percentile) for triglycerides, PTH, UPCR and eGFR slope. The study patients were classified into four groups according to quartiles of UPCR. Among-group comparisons were performed using one-way analysis of variance followed by a Bonferroni-adjusted post hoc test. Multivariate stepwise linear regression analysis was used to identify factors associated with AoAC, CTR and eGFR slope. Survival curves for dialysis-free, overall and CV survival were plotted using the Kaplan-Meier method. The time to commencing dialysis, overall and CV mortality and covariates of risk factors were modeled using a multivariable forward Cox proportional hazards model. The patients in quartile 1, who had the lowest risk of mortality, served as the reference group. P < 0.05 was considered to indicate a significant difference.

Results

A total of 482 patients (283 men and 199 women) with CKD stage 3A-5 were included, with a mean age of 65.5 ± 12.2 years. The patients were classified into four groups according to quartiles of UPCR. The clinical characteristics of these four groups are shown in Table 1. There were 116, 124, 119 and 123 patients in the four groups, respectively. Compared to the patients in quartile 1, more of those in quartile 4 were female, and they had higher prevalence rates of diabetes mellitus and hypertension, higher systolic blood pressure, higher CTR, higher levels of triglycerides and total cholesterol, lower total calcium, higher phosphorous, higher calcium-phosphorous product, higher PTH, higher UPCR, lower hemoglobin, lower baseline eGFR, higher prevalence of advanced CKD stage and higher percentage of calcium-based phosphate binders use. With regards to the outcomes, the patients in quartile 4 had a lower eGFR slope, more rapid renal progression, progression to commencement of dialysis, overall and CV mortality compared to those in quartile 1.

Figure 1 illustrates the eGFR slopes of the four study groups, with median values of -1.31, -1.64, -3.18, and -4.78 ml/min/1.73 m²/year, respectively. The patients in quartile 4 had the lowest eGFR slope.

Determinants of AoAC

Table 2 shows the determinants of AoAC in all patients. In the multivariate stepwise linear regression analysis after adjusting for age, sex, body mass index, smoking status, cerebrovascular disease, coronary artery disease, hypertension, systolic and diastolic blood pressures, diabetes mellitus, fasting glucose, hemoglobin, log-transformed triglycerides, total cholesterol, hemoglobin, baseline eGFR, total calcium, phosphorous, calcium-phosphorous product, uric acid, PTH, log-transformed UPCR, ACEI/ARB antihypertensive drug and calcium-based phosphate binders use, old age, high calcium-phosphorous product, low PTH, and high UPCR (unstandardized coefficient β: 0.315; 95% confidence interval [CI], 0.119 to 0.511; p = 0.002) were independently correlated with high AoAC.

Determinants of CTR

Table 3 shows the determinants of CTR in all patients. In the multivariate stepwise linear regression analysis, old age, male sex (vs. female), coronary artery disease, cerebrovascular disease, high body mass index, low hemoglobin, high uric acid, high UPCR (unstandardized coefficient β: 1.186; 95% CI, 0.130 to 2.242; p = 0.028), and calcium-based phosphate binders use were independently associated with high CTR.
The study patients were stratified into 4 groups according to quartiles of urine protein-to-creatinine ratio.

**Table 1. Comparison of clinical characteristics according to quartiles of urine protein-to-creatinine ratio (Upcr)**

| Characteristics                  | Quartile 1 (n = 116) | Quartile 2 (n = 124) | Quartile 3 (n = 119) | Quartile 4 (n = 123) | p     |
|----------------------------------|----------------------|----------------------|----------------------|----------------------|-------|
| Age (year)                       | 67.2 ± 12.8          | 64.7 ± 12.4          | 65.8 ± 12.5          | 63.8 ± 11.1          | 0.074 |
| Male gender (%)                  | 67.2                 | 65.3                 | 57.1                 | 45.5†                | 0.002 |
| Smoking (%)                      | 30.6                 | 33.1                 | 28.6                 | 20.3                 | 0.149 |
| Diabetes mellitus (%)            | 45.7                 | 48.4                 | 57.6                 | 82.9**               | < 0.001 |
| Hypertension (%)                 | 80.2                 | 82.3                 | 91.5                 | 94.3†                | 0.001 |
| Coronary artery disease (%)      | 13.8                 | 12.2                 | 14.5                 | 13.0                 | 0.958 |
| Cerebrovascular disease (%)      | 9.5                  | 12.9                 | 7.6                  | 6.6                  | 0.332 |
| Systolic blood pressure (mmHg)   | 137.8 ± 19.2         | 139.4 ± 21.9         | 146.0 ± 22.4         | 154.3 ± 24.6**       | < 0.001 |
| Diastolic blood pressure (mmHg)  | 76.9 ± 13.3          | 78.1 ± 13.0          | 79.0 ± 15.3          | 76.9 ± 14.8          | 0.620 |
| Body mass index (kg/m²)          | 25.6 ± 3.5           | 25.3 ± 3.9           | 25.5 ± 4.0           | 25.6 ± 4.1           | 0.926 |
| AsoAC (%)                        | 3.5 ± 1.1            | 3.6 ± 0.8            | 3.8 ± 0.8            | 3.8 ± 0.9            | 0.020 |
| CTR (%)                          | 47.8 ± 5.1           | 48.3 ± 5.2           | 50.5 ± 5.8†          | 51.5 ± 5.8†          | < 0.001 |
| Laboratory parameters            |                      |                      |                      |                      |       |
| Fasting glucose (mg/dL)          | 120.3 ± 45.3         | 124.3 ± 52.6         | 123.4 ± 53.3         | 136.9 ± 63.2         | 0.086 |
| Triglyceride (mg/dL)             | 121 (90-193.5)       | 142 (90-205.5)       | 132 (97-187)         | 148 (115-208)*       | 0.041 |
| Total cholesterol (mg/dL)        | 188.4 ± 44.0         | 197.6 ± 56.8         | 193.2 ± 52.2         | 219.0 ± 65.1**       | < 0.001 |
| Hemoglobin (g/dL)                | 12.6 ± 2.0           | 11.4 ± 2.3           | 10.9 ± 2.2           | 10.0 ± 1.8†          | < 0.001 |
| Baseline eGFR (ml/min/1.73m²)    | 34.5 ± 12.0          | 25.9 ± 14.4          | 20.6 ± 12.3†         | 18.7 ± 10.6†         | < 0.001 |
| CKD stage (%)                    | 16.4                 | 8.1                  | -                    | -                    | < 0.001 |
| 3A (%)                           | 44.0                 | 27.4                 | 16.8                 | 11.4                 |       |
| 4 (%)                            | 37.9                 | 37.9                 | 42.0                 | 41.5                 |       |
| 5 (%)                            | 1.7                  | 26.6                 | 38.7                 | 44.7                 |       |
| Total calcium (mg/dL)            | 9.4 ± 0.5            | 9.4 ± 0.9            | 9.2 ± 0.7*           | 8.9 ± 0.8**          | < 0.001 |
| Phosphorous (mg/dL)              | 3.6 ± 0.6            | 4.0 ± 1.1†           | 4.2 ± 1.0            | 4.5 ± 1.0†           | < 0.001 |
| Calcium-phosphorous product (mg/dL²) | 34.2 ± 5.6         | 37.5 ± 9.4           | 38.4 ± 8.1†          | 39.5 ± 8.9           | < 0.001 |
| Uric acid (mg/dL)                | 8.4 ± 2.4            | 8.0 ± 2.0            | 8.2 ± 1.9            | 8.3 ± 2.0            | 0.497 |
| PTH (pg/mL)                      | 40.6 (29.6-60.8)     | 46.1 (26.6-110.2)    | 85.8 (49.5-173.3)†   | 118.5 (59.3-222.4)†  | < 0.001 |
| Upcr (mg/g)                      | 166.5 (90.3-284.2)   | 864 (666-1030.6)     | 1975 (1560-2322)†    | 4950 (3435-8211)†    | < 0.001 |
| Medications                      |                      |                      |                      |                      |       |
| ACEI and/or ARB use              | 67.2                 | 57.3                 | 53.8                 | 56.1                 | 0.164 |
| Calcium-based phosphate binders  | 0                    | 5.2                  | 8.3                  | 14.8†                | 0.003 |
| Outcome                          |                      |                      |                      |                      |       |
| eGFR slope (ml/min/1.73 m²/yr)   | -1.31 (-2.16, -0.11) | -1.64 (-3.13, -0.72) | -3.18 (-5.03, -1.52) | -4.78 (-7.55, -2.42)** | < 0.001 |
| eGFR slope < -3 ml/min/1.73 m²/yr (%) | 14.7              | 25.8                 | 52.1†                | 69.9**               | < 0.001 |
| Progression to dialysis (%)      | 4.3                  | 25.8                 | 47.1†                | 60.2†                | < 0.001 |
| Overall mortality (%)            | 8.6                  | 18.5                 | 18.5                 | 25.2                 | 0.010 |
| Cardiovascular mortality (%)     | 0.9                  | 5.6                  | 8.4                  | 10.6*                | 0.015 |

Abbreviations: AsoAC, aortic arch calcification; CTR, cardiothoracic ratio; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; PTH, parathyroid hormone; Upcr, Urine protein-to-creatinine ratio; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

The study patients were stratified into 4 groups according to quartiles of urine protein-to-creatinine ratio.

*p < 0.05 compared with quartile 1; **p < 0.05 compared with quartile 2; †p < 0.05 compared with quartile 3.

![Figure 1](http://www.medsci.org)
Table 2. Determinants of AoAC using multivariable stepwise linear regression analysis in study patients

| Parameter                              | Multivariate (Stepwise) | Unstandardized coefficient β | p      |
|----------------------------------------|-------------------------|------------------------------|--------|
| Age (per 1 year)                       | 0.017 (0.008, 0.026)    | < 0.001                      |        |
| Calcium-phosphorous product (1 mg/dL)  | 0.020 (0.007, 0.033)    | 0.003                        |        |
| PTH (per 1 pg/mL)                      | -0.001 (-0.002, 0.000)  | 0.940                        |        |
| UPCR (log per 1 mg/g)                  | 0.315 (0.119, 0.511)    | 0.002                        |        |

Values expressed as unstandardized coefficient β and 95% confidence interval (CI). Abbreviations are the same as in Table 1. Adjusted for age, gender, smoking, diabetes mellitus, hypertension, coronary artery disease, cerebrovascular disease, systolic and diastolic blood pressures, body mass index, fasting glucose, log-transformed triglyceride, total cholesterol, hemoglobin, baseline eGFR, total calcium, phosphorous, calcium-phosphorous product, uric acid, PTH, log-transformed UPCR, ACEI/ARB antihypertensive drug and calcium-based phosphate binders use.

Table 3. Determinants of CTR using multivariable stepwise linear regression analysis in study patients

| Parameter                              | Multivariate (Stepwise) | Unstandardized coefficient β | p      |
|----------------------------------------|-------------------------|------------------------------|--------|
| Age (per 1 year)                       | 0.087 (0.038, 0.135)    | 0.001                        |        |
| Male (vs. female)                      | 2.953 (1.692, 4.213)    | < 0.001                      |        |
| Coronary artery disease                | 1.944 (0.259, 3.630)    | 0.024                        |        |
| Cerebrovascular disease                | 3.728 (1.665, 7.90)     | < 0.001                      |        |
| Body mass index (per 1 kg/m²)          | 0.210 (0.055, 0.365)    | 0.008                        |        |
| Hemoglobin (per 1 g/dL)                | -0.364 (-0.677, -0.050) | 0.023                        |        |
| Uric acid (per 1 mg/dL)                | 0.464 (0.185, 0.744)    | 0.001                        |        |
| UPCR (log per 1 mg/g)                  | 1.186 (0.130, 2.242)    | 0.028                        |        |
| Calcium-based phosphate binders use    | 2.475 (0.175, 4.775)    | 0.035                        |        |

Values expressed as unstandardized coefficient β and 95% confidence interval (CI). Abbreviations are the same as in Table 1. Adjusted for age, gender, smoking, diabetes mellitus, hypertension, coronary artery disease, cerebrovascular disease, systolic and diastolic blood pressures, body mass index, fasting glucose, log-transformed triglyceride, total cholesterol, hemoglobin, baseline eGFR, total calcium, phosphorous, calcium-phosphorous product, uric acid, PTH, log-transformed UPCR, ACEI/ARB antihypertensive drug and calcium-based phosphate binders use.

Table 4. Determinants of eGFR slope using multivariable stepwise linear regression analysis in study patients

| Parameter                              | Multivariate (Stepwise) | Unstandardized coefficient β | p      |
|----------------------------------------|-------------------------|------------------------------|--------|
| Diastolic blood pressure (per 1 mmHg)  | 0.030 (0.005, 0.055)    | 0.019                        |        |
| Uric acid (per 1 mg/dL)                | -0.185 (-0.651, -0.019) | 0.029                        |        |
| UPCR (log per 1 mg/g)                  | -2.396 (-2.965, -1.831) | < 0.001                      |        |

Values expressed as unstandardized coefficient β and 95% confidence interval (CI). Abbreviations are the same as in Table 1. Adjusted for age, gender, smoking, diabetes mellitus, hypertension, coronary artery disease, cerebrovascular disease, systolic and diastolic blood pressures, body mass index, fasting glucose, log-transformed triglyceride, total cholesterol, hemoglobin, baseline eGFR, total calcium, phosphorous, calcium-phosphorous product, uric acid, PTH, log-transformed UPCR, ACEI/ARB antihypertensive drug and calcium-based phosphate binders use.

Determinants of eGFR slope

Table 4 shows the determinants of eGFR slope in all patients. In the multivariate stepwise linear regression analysis, low diastolic blood pressure, high uric acid, and high UPCR (unstandardized coefficient β: -2.396; 95% CI, -2.965 to -1.831; p < 0.001) were independently correlated with larger negative values of the eGFR slope.

Risk of Progression to Dialysis

The follow-up period was 4.4 (2.8-7.3) years, during which 167 patients (34.6%) started hemodialysis. Table 5 shows the hazard ratios (HRs) for age, sex, body mass index, smoking status, cerebrovascular disease, coronary artery disease, hypertension, systolic and diastolic blood pressures, diabetes mellitus, fasting glucose, log-transformed triglyceride, total cholesterol, hemoglobin, baseline CKD stage, total calcium, phosphorous, calcium-phosphorous product, uric acid, PTH, log-transformed UPCR, ACEI/ARB antihypertensive drug and calcium-based phosphate binders use, and quartiles of UPCR (model 1) or log-transformed UPCR (model 2). The multivariate regression analysis (model 1) showed that compared to those in quartile 1 of UPCR, those in quartile 3 (HR, 6.731; 95% CI, 1.531 to 29.600; p = 0.012), and quartile 4 (HR, 6.639; 95% CI, 1.466 to 30.075; p = 0.014) were significantly associated with progression to dialysis. In the multivariate regression analysis (model 2), increased UPCR (log per 1 mg/g; HR, 2.538; 95% CI, 1.375 to 4.685; p = 0.003) was significantly correlated with progression to dialysis.

Figure 2 illustrates the Kaplan-Meier analysis of dialysis-free survival (log-rank p < 0.001) among four study groups. The patients in quartiles 2, 3, and 4 of UPCR had worse dialysis-free survival than those in quartile 1.

Risk of Overall Mortality

The median follow-up period was 5.7 (3.6-8.0) years, during which 86 of the 482 patients died (17.8%) due to CV causes (n = 31), malignancy (n = 7), infectious diseases (n = 40), gastrointestinal bleeding (n = 4), and others (n = 4). The multivariate regression analysis (model 1) showed that compared to the patients in quartile 1 of UPCR, those in quartile 3 (HR, 3.452; 95% CI, 1.179 to 10.109; p = 0.024), and quartile 4 (HR, 4.845; 95% CI, 1.805 to 12.999; p = 0.002) were significantly associated with increased overall mortality (Table 5). Further, model 2 of the multivariate regression analysis showed that increased UPCR (log per 1 mg/g; HR, 2.292; 95% CI, 1.329 to 3.953; p = 0.003) was also significantly associated with increased overall mortality.

Figure 3 illustrates the Kaplan-Meier analysis of overall survival (log-rank p = 0.021) among the four study groups. The patients in quartile 4 of UPCR had worse overall survival than those in quartile 1.

Risk of CV Mortality

The 31 patients who died due to CV causes during follow-up included heart failure (n = 8), myocardial infarction (n = 6) and ventricular
fibrillation (n = 17). Multivariate forward Cox proportional hazards regression analysis of CV mortality in the four study groups is shown in Table 5. The patients in quartile 3 of UPCR (HR, 11.741; 95% CI, 1.422 to 96.935; p = 0.022) and quartile 4 (HR, 12.974; 95% CI, 1.642 to 102.481; p = 0.015) (vs. quartile 1 of UPCR) in model 1, and increased UPCR (log per 1 mg/g; HR, 3.195; 95% CI, 1.393 to 7.325; p = 0.006) in model 2 were significantly associated with increased CV mortality.

Figure 4 illustrates the Kaplan-Meier analysis of CV survival (log-rank p = 0.019) among the four study groups. The patients in quartile 3 and quartile 4 of UPCR had worse CV survival than those in quartile 1.

Figure 2. Kaplan-Meier analyses of dialysis-free survival (log-rank p < 0.001) among 4 study groups. The group with quartile 2, quartile 3, and quartile 4 of UPCR had worse dialysis-free survival than that with quartile 1 of UPCR.

Figure 3. Kaplan-Meier analyses of overall survival (log-rank p = 0.021) among 4 study groups. The group with quartile 4 of UPCR had worse overall survival than that with quartile 1 of UPCR.
Figure 4. Kaplan-Meier analyses of cardiovascular survival (log-rank \( p = 0.019 \)) among 4 study groups. The group with quartile 3 and quartile 4 of UPCR had worse overall survival than that with quartile 1 of UPCR.

Table 5. Relation of UPCR quartiles and log-transformed UPCR to progression to dialysis, overall and cardiovascular mortality using multivariate forward Cox proportional hazards model in study patients

| Parameters | Commencement of dialysis | Overall mortality | Cardiovascular mortality |
|------------|--------------------------|-------------------|-------------------------|
|            | Hazard ratio (95% CI)    | \( p \)           | Hazard ratio (95% CI)    | \( p \) |
| Model 1    |                          |                  |                          |
| Quartile 1 of UPCR | Reference               | Reference         | Reference               |
| Quartile 2 of UPCR | 3.476 (0.769-15.708)    | 0.105             | 1.844 (0.626-5.428)     | 0.267            | 3.853 (0.428-34.713) | 0.229 |
| Quartile 3 of UPCR | 6.731 (1.531-29.600)    | 0.012             | 3.452 (1.179-10.109)   | 0.024            | 11.741 (1.422-96.935) | 0.022 |
| Quartile 4 of UPCR | 6.639 (1.466-30.075)    | 0.014             | 4.845 (1.805-12.999)   | 0.002            | 12.974 (1.642-102.481) | 0.015 |
| Model 2    |                          |                  |                          |
| UPCR (log per 1 mg/g) | 2.538 (1.375-4.685) | 0.003             | 2.292 (1.329-3.953)    | 0.003            | 3.195 (1.393-7.325) | 0.006 |

Values expressed as hazard ratio and 95% confidence interval (CI). Abbreviations are the same as in Table 1.

Multivariate model 1: adjusted for age, gender, smoking, diabetes mellitus, hypertension, coronary artery disease, cerebrovascular disease, systolic and diastolic blood pressures, body mass index, fasting glucose, log-transformed triglyceride, total cholesterol, hemoglobin, baseline CKD stage, total calcium, phosphorous, calcium-phosphorous product, uric acid, PTH, log-transformed UPCR, ACEI/ARB antihypertensive drug and calcium-based phosphate binders use.

Multivariate model 2: adjusted for age, gender, smoking, diabetes mellitus, hypertension, coronary artery disease, cerebrovascular disease, systolic and diastolic blood pressures, body mass index, fasting glucose, log-transformed triglyceride, total cholesterol, hemoglobin, baseline CKD stage, total calcium, phosphorous, calcium-phosphorous product, uric acid, PTH, log-transformed UPCR, ACEI/ARB antihypertensive drug and calcium-based phosphate binders use.

Discussion

This study demonstrated associations among proteinuria and renal function progression, overall and CV mortality in patients with CKD stages 3–5. We found that high U\(_{\text{PCR}}\) was associated with a rapid decline in renal function, high AoAC and high CTR. In addition, the patients with high U\(_{\text{PCR}}\) had a higher risk of progression to dialysis, overall and CV mortality.

To the best of our knowledge, this is the first study to report an association between high U\(_{\text{PCR}}\) and high AoAC as measured from chest X-rays in patients with CKD stages 3–5. Dayan et al. reported an association between coronary artery calcification and albuminuria in patients with type 2 diabetes (16). Similarly, Freedman et al. also reported an association between albuminuria and calcified plaques in coronary and carotid arteries in 588 patients with type 2 diabetes (17). However, a study conducted by Li et al. showed that age, eGFR slope, and increased CTR were independent determinants of AoAC, but that proteinuria was not (9). Another study also reported an independent association between descending thoracic aortic calcium and eGFR, but not with urinary albumin to creatinine ratio (U\(_{\text{ACR}}\)) (18). Thus, the status of proteinuria as a risk marker for VC remains controversial. In CKD, interstitial capillaries become increasingly permeable, allowing plasma proteins to reach the renal interstitium and trigger an
inflammatory response. In vitro, exposure of proximal tubular cells to plasma proteins including albumin, transferrin and IgG has been shown to result in the release of pro-inflammatory and pro-fibrotic molecules including interleukin-8 (IL-8), NF-kappaB, endothelin-1 (ET-1), monocyte chemoattractant protein-1 (MCP-1), regulated on activation normal T expressed and secreted (RANTES) chemokine, fractalkine, and osteopontin (19-22). Moreover, ET-1, NF-kappaB, interleukin (IL)-8 and osteopontin have been shown to be potent regulators of VC in vivo (23-26). VC can occur in the tunica intima or tunica media of the arterial wall, or both, and the clinical consequences of intimal versus medial layer calcification can be quite different. For example, intimal calcification is associated with plaque rupture and acute vessel occlusion, whereas increased arterial stiffness is associated with medial calcification (27). Inflammation and oxidative stress are involved in the process of VC (10). Inflammatory cytokines such as tumor necrosis factor and IL-6 have been reported to induce the differentiation of vascular smooth muscle cells and VC. In addition, inflammation has also been associated with the production of reactive oxygen species, which can then further induce vascular remodeling and VC (10). Moreover, proteinuria promotes the inflammation mediated by these cytokines, leading to increased AoAC.

Another important finding of this study is that a high U\textsubscript{PCR} were associated with a high CTR in the patients with CKD stages 3-5. Previous studies have assessed LVM using electrocardiography, echocardiography, and magnetic resonance imaging (28-30). The MONICA/KORA study demonstrated that even low levels of albuminuria was a significant predictor of LVM assessed using echocardiography in the general population (28). Using Cornell electrocardiographic voltage criteria, Nobakhthaghi et al. reported associations among LVM, urinary albumin excretion and mortality in patients with type 2 diabetes (29). In addition, proteinuria has been independently and significantly associated with LVM as measured by cardiac magnetic resonance imaging in patients with CKD (30). Recently, Matsushita et al. investigated cross-sectional associations between eGFR and albuminuria with LVM in the Atherosclerosis Risk in Communities Study, and found that both higher albuminuria and lower eGFR were independently associated with left ventricular structure and function electrocardiographic parameters (31). The pathophysiology of cardiomegaly in patients with CKD is multifactorial in origin. Patients with CKD often have VC, which can lead to increased systemic arterial resistance, higher arterial blood pressure, and a reduction in large-vessel compliance, resulting in myocardial cell thickening and concentric remodeling of the left ventricle (32). As mentioned, proteinuria, left ventricular hypertrophy and VC interact with each other and share common pathways including oxidative stress. In addition, Chen et al. demonstrated that CTR could be an indicator of inflammation in patients without diabetes on hemodialysis (33).

The third important finding in this study is that a high U\textsubscript{PCR} was associated with a rapid decline in renal function and a higher risk of progression to dialysis in the patients with CKD stages 3-5. Tubular atrophy, interstitial fibrosis and scarring are closely associated with glomerular filtration rate and proteinuria. The abnormal filtration of various urinary proteins including cytokines, complement, and albumin can stimulate tubular epithelial cells to produce inflammatory products including chemokines and reactive oxygen species. This then causes inflammatory cells to enter the renal interstitium and interact with interstitial myofibroblasts. As fibrosis develops, injured tubular epithelia are no longer able to regenerate and undergo apoptosis, thereby leading to tubular atrophy with nonfunctioning glomeruli (34).

Previous studies have reported a strong association between proteinuria and the risk of CKD progression (35-38). A study involving 107,192 participants in Okinawa, Japan, identified proteinuria as the most powerful predictor of the risk of ESRD over 10 years in the general population (35). The African-American Study of Kidney Disease and Hypertension (AASK) included patients without diabetes but with CKD and found that a higher baseline proteinuria level was associated with a faster decline in glomerular filtration rate (36). In addition, among patients with diabetic nephropathy, baseline U\textsubscript{ACR} was a strong independent predictor of ESRD in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study and in the Irbesartan in Diabetic Nephropathy Trial (IDNT) (37, 38). Moreover, Inker et al. reported that an early reduction in proteinuria was associated with a slower progression of kidney disease, and that this association was stronger in the patients with higher levels of baseline proteinuria (39).

Another finding of this study is that a high U\textsubscript{PCR} was associated with a higher risk of overall and CV mortality in the patients with CKD stages 3-5. This is consistent with previous studies which reported an association between proteinuria and overall and CV mortality (40, 41). A large meta-analysis of general population cohorts analyzed 21 studies with more than 100,000 individuals with U\textsubscript{ACR}, and found that the relationship between albuminuria and mortality...
was linear on a log-log scale, with a 2-fold higher risk at a U_{ACR} of approximately 100 mg/g compared to an optimal U_{ACR} level (5 mg/g) independently of eGFR and conventional risk factors (40). Another systematic review and meta- and pooled analyses of seven prospective cohorts in Japan demonstrated that proteinuria was associated with a 1.75-fold (95% CI: 1.44, 2.11) increased risk of CV disease mortality after adjusting for potential confounding factors (41). In addition, patients with both proteinuria and a eGFR of <45 mL/minute/1.73 m² had a 4.05 -fold (95% CI: 2.55, 6.43) higher risk of CV disease mortality compared to those with neither of these risk factors. The association between microalbuminuria and CV disease may be due to common pathophysiologic processes, such as endothelial dysfunction or chronic low-grade inflammation (42). The present study clearly showed that proteinuria was associated with the risk of overall and CV disease mortality, which supports the view that assessing proteinuria is needed to improve the identification of individuals at high risk of CV complications and to establish appropriate preventative measures for these patients.

There are several limitations to this study. First, the study patients were enrolled from one regional hospital in southern Taiwan, and thus, the generalizability of our results is limited. Second, this was an observational study, and there were variations in the frequency and number of laboratory examinations between patients, including serum creatinine measurements. To minimize this effect, we excluded patients who were followed for less than 6 months or had fewer than three eGFR measurements during the follow-up period. Third, only one radiologist assessed CTR and AoAC on the chest radiographs, and therefore observation bias may have existed. We tested the reproducibility of AoAC by having another trained medical doctor screen some of the chest plain films and calculating the mean percent error. Fourth, CTR and AoAC were measured only once at enrollment. Therefore, the association between the effect of AoAC and CTR over time could not be estimated.

In conclusion, this is the first study to report an association between a high U_{PCR} and high AoAC and CTR in patients with CKD stages 3–5. Furthermore, a high degree of proteinuria was correlated with a rapid decline in renal function, the risk of progression to dialysis, and overall and CV mortality. Assessments of proteinuria may be beneficial to allow for the early identification of high-risk patients and initiate interventions to prevent VC, cardiomegaly, rapid decline in renal function, progression to dialysis, and to increase overall, dialysis-free and CV survival.

Acknowledgements

The research presented in this article is supported by the grants from the Kaohsiung Municipal Hsiao-Kang Hospital (kmhk-108-S-001), Kaohsiung Medical University, Kaohsiung, Taiwan.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Kuznik A, Mardekian J, Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010. BMC Nephrol 2013; 14: 132.
2. Levey AS, de Jong PF, Corregh J, El Nahas M, Astor BC, Matsuishi K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28.
3. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 239-50.
4. Hwang HS, Cho JS, Hwang YA, Chang YK, Kim YS, Shin SJ, et al. Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts. Int J Med Sci 2018; 15: 557-63.
5. Lee C-T, Huang C-C, Hsu C-Y, Chou T-T-Y, Ng H-Y, Wu C-H, et al. Calculation of the Aortic Arch Predicts Cardiovascular and All-Cause Mortality in Chronic Hemodialysis Patients. Cardiorenal Med 2014; 4: 34-42.
6. Hashimoto H, Iijima K, Hashimoto M, Son B-K, Ota H, Ogawa S, et al. Validity and Usefulness of Aortic Arch Calcification in Chest X-Ray. J Atheroscler Thromb 2009; 16: 256-64.
7. Rayner B. The chest radiograph useful investigation in the evaluation of hypertensive patients. Am J Hypertens 2004; 17: 507-10.
8. Yotsueda R, Taniguchi M, Tanaka S, Eriguchi M, Fujisaki K, Torisu K, et al. Cardiothoracic Ratio and All-Cause Mortality and Cardiovascular Disease Events in Hemodialysis Patients: The Q-Cohort Study. Am J Kidney Dis 2017; 70: 84-92.
9. Li L-C, Lee Y-T, Lee Y-W, Chou C-A, Lee C-T. Aortic arch calcification predicts the renal function progression in patients with stage 3 to 5 chronic kidney disease. Biomed Res Int 2015; 2015: 131263.
10. Chen S-C, Teh M, Huang J-C, Wu P-Y, Chen Y-C, Tsai Y-C, et al. Increased Aortic Arch Calcification and Cardiomegaly is Associated with Rapid Renal Progression and Increased Cardiovascular Mortality in Chronic Kidney Disease. Sci Rep 2019; 9: 5354.
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
12. Ogawa T, Ishida H, Matsuoa N, Fujiu A, Matsuoa A, Ito K, et al. Simple method of assessing aortic arch calcification by chest radiography in hemodialysis patients. Hemodial Int 2009; 13: 301-6.
13. Vickery S, Stevens PE, Dalton RN, van Lente F, Lamb EJ. Does the ID-MS traceable MDRD equation work and is it suitable for use with compensated Jaffe and enzymatic creatinine assays? Nephrol Dial Transplant 2006; 21: 2439-45.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
15. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 2009; 20: 2625-30.
16. Dayan A, Narin B, Biterer M, Aksoy S, Fotbolcu H, Duman D. Coronary calcium score, albuminuria and inflammatory markers in type 2 diabetic patients: associations and prognostic implications. Diabetes Res Clin Pract 2012; 98: 98-103.
17. Freedman BI, Langedfeld CD, Lohman KK, Bowden DW, Car J, Rich SS, et al. Relationship between Albuminuria and Cardiovascular Disease in Type 2 Diabetes. J Am Soc Nephrol 2005; 16: 2156-61.
18. Roos CJ, Delgado V, de Koning EJ, Rabelink TJ, Jukema JW, Bax JJ, et al. Associations of atherosclerosis in the descending thoracic aorta on CTA with arterial stiffness and chronic kidney disease in asymptomatic patients with diabetes mellitus. Int J Card Imaging 2014; 30: 1151-9.
19. Zoja C, Morici M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, et al. Proximal tubule cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995; 26: 934-41.
20. Drumm K, Bauer B, Freudinger R, Gekke M. Albumin induces NF-kappaB expression in human proximal tubule-derived cells (IHKE-1). Cell Physiol Biochem 2002; 12: 187-96.
21. Tang S, Leung JC, Abe K, Chan KW, Chan LY, Chan TM, et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003; 111: 515-27.

22. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17: 2974-84.

23. Wu SY, Zhang BH, Pan CS, Jiang HF, Pang YZ, Tang CS, et al. Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells. Peptides 2003; 24: 1149-56.

24. Zhao G, Xu MJ, Zhao MM, Dai XY, Kong W, Wilson CM, et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int 2012; 82: 34-44.

25. Bouabdallah J, Zihara K, Issa H, Lenglet G, Khour G, Caas T, et al. Endothelial cells exposed to phosphate and indoxyl sulphate promote vascular calcification through interleukin-8 secretion. Nephrol Dial Transplant 2019; 34: 1125-34.

26. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of Vascular Calcification. Circ Res 2005; 96: 717-22.

27. Vervloet M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int 2017; 91: 808-17.

28. Lieb W, Mayer B, Stritzke J, Doering A, Henne H-W, Loewel H, et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant 2006; 21: 2780-7.

29. NobakhtBaghighi N, Kangar M, Bekerheima MR, McFann K, Estacio R, Schrier RW. Relationship between Urinary Albumin Excretion and Left Ventricular Mass with Mortality in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol 2006; 1: 1187-90.

30. McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, et al. Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 933-8.

31. Matsushita K, Kwak L, Sang Y, Ballegow SH, Skali H, Shah AM, et al. Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc 2017; 6: e006259.

32. Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment. Cardiorenal Med 2015; 5: 254-66.

33. Chen K-H, Lin-Tan D-T, Huang W-H, Loewel H, Kimura C, Chang C-T, Huang J-Y, et al. Cardiothoracic ratio, malnutrition, inflammation, and two-year mortality in non-diabetic patients on maintenance hemodialysis. Kidney Blood Press Res 2008; 31: 143-51.

34. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet 2017; 389: 1258-52.

35. Inker LA, Levey AS, Panda K, Stoycheff N, Okparavero A, Greene T. Early change in proteinuria as a surrogate end point for kidney disease progression: results from the AASK trial. JAMA 2002; 288: 2421-31.

36. Keane WF, Zhang Z, Lyle PA, Cooper MF, de Zeeuw D, Grunfeld JP, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol 2006; 1: 741-7.

37. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-7.

38. Inker LA, Levey AS, Panda K, Stoycheff N, Okparavero A, Greene T. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 2014; 64: 74-85.

39. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.

40. Nagata M, Ninomiya T, Kiyohara Y, Murakami Y, Irie F, Sairenchi T. Prediction of Cardiovascular Disease Mortality by Proteinuria and Reduced Kidney Function: Pooled Analysis of 39,000 Individuals From 7 Cohort Studies in Japan. Am J Epidemiol 2010; 171: 1-11.

41. Stehouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 2006; 17: 2106-11.